Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclin b1 + wilms' tumor protein 1 + CEF + dendritic cell vaccine
- Development stage
- Phase 2
- Lead developer
- University of Pittsburgh
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
This therapeutic agent is an autologous dendritic cell (DC) vaccine designed to stimulate a robust anti-tumor immune response. It consists of patient-derived dendritic cells that are matured ex vivo and pulsed with a combination of tumor-associated antigens (TAAs) and control peptides. The primary components include peptides from **Cyclin B1**, a regulatory protein often overexpressed in various malignancies, and **Wilms' Tumor Protein 1 (WT1)**, a transcription factor frequently found in leukemias and solid tumors. The vaccine also includes **CEF peptides** (derived from Cytomegalovirus, Epstein-Barr Virus, and Influenza) which serve as a positive control and adjuvant to boost memory T-cell responses. By presenting these specific antigens via the Major Histocompatibility Complex (MHC) pathways, the vaccine aims to activate and expand tumor-specific cytotoxic T lymphocytes (CTLs) capable of identifying and eliminating cancer cells expressing Cyclin B1 and WT1.
- Other names
- multi-antigen dendritic cell vaccineDCV-CB1-WT1-CEFDCV-CB-1-WT1-CEFDCV-CB 1-WT1-CEFcyclin b1/WT1/CEF-pulsed dendritic cell vaccine
02
Targets
WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on cyclin b1 + wilms' tumor protein 1 + CEF + dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclin b1 + wilms' tumor protein 1 + CEF + dendritic cell vaccine.